Peptides for Cardiac Biomarker
Reviewed by Marcus Hopkin, PhD
Director of Research and Development, Volta Peptides
Written by Volta Peptides Editorial Team · Reviewed September 15, 2026
This guide provides a detailed examination of two peptides that have been the focus of research as cardiac biomarkers. These compounds are ranked according to the strength of evidence supporting their use, ranging from FDA-approved status to those under early preclinical investigation. Each peptide is evaluated based on its underlying mechanism of action, clinical relevance, safety profile, and current regulatory status. This comprehensive overview aims to facilitate informed decisions in the context of cardiac biomarker research.
Overview
2 research peptides are currently studied for cardiac biomarker. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.
Atrial Natriuretic Peptide — Approved in Japan / Established Biomarker
Atrial natriuretic peptide (ANP), a 28-amino-acid hormone with a molecular weight of approximately 3080 g/mol, is secreted primarily by atrial cardiomyocytes in response to increased atrial stretch due to volume overload. ANP plays a pivotal role in regulating blood volume, sodium homeostasis, and blood pressure, contributing to cardiovascular health. The recombinant form, carperitide (hANP), is approved in Japan for the management of acute heart failure, although it lacks approval in Western markets. Research indicates that ANP effectively reduces pulmonary congestion and alleviates dyspnea in acute heart failure patients. Furthermore, its natriuretic and diuretic properties have been well-documented, making it a valuable biomarker for assessing heart failure severity. However, while its clinical utility is established in specific contexts, further studies are needed to elucidate its long-term safety profile and efficacy in broader populations.
B-type Natriuretic Peptide — Established Biomarker / Therapeutic Basis
B-type natriuretic peptide (BNP), a 32-amino-acid cardiac hormone with a molecular weight of approximately 3464 g/mol, is primarily secreted by ventricular cardiomyocytes in response to myocardial wall stress resulting from either volume overload or pressure overload. BNP serves a dual role as a critical diagnostic biomarker for heart failure, with assays measuring BNP and its inactive fragment NT-proBNP widely employed in clinical settings. Additionally, BNP forms the basis for the therapeutic agent nesiritide, a recombinant version of BNP that has been utilized in treating acute heart failure. Historical research, initially identifying BNP in porcine brain tissue, has led to its designation as 'brain natriuretic peptide.' Studies indicate that elevated BNP and NT-proBNP levels correlate with heart failure severity and can guide therapeutic interventions, potentially improving patient outcomes. However, while BNP-guided therapy shows promise, the variability in responses among different patient populations necessitates further investigation to optimize its clinical application.
Shop Research Peptides
Cagrilintide 5mg
DSIP 10mg
Epithalon 10mg
GHRP-2 5mg
5mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Peptide Tools
Key research references
- Best Peptides for Anti-Aging | Research Guide
- Best Peptides for Metabolic Health | Research Guide
- Best Peptides for Weight Management | Research Guide
- Best Peptides for Body Composition | Research Guide
- Best Peptides for Reproductive Health | Research Guide
- Best Peptides for Anti-Aging & Longevity | Research Guide
- Best Peptides for Weight Loss | Research Guide
- Best Peptides for Cognitive Enhancement | Research Guide
- Retatrutide Dosing Guide | Protocols & Reconstitution
- Wound Healing Peptides | Research Compounds
- Muscle Growth Peptides | Research Compounds
- Immune Modulation Peptides | Research Compounds
Browse the research catalogue
Buying and verification
Frequently Asked Questions
Related Resources
Related Research
About the reviewer
Director of Research and Development, Volta Peptides
Marcus Hopkin, PhD, is Director of Research and Development at Volta Peptides. He has more than 12 years of analytical chemistry experience, including direct laboratory work in peptide synthesis, characterization, purity testing and stability assessment. His doctoral research at the University of Michigan examined novel peptide structures in the human proteome and their potential significance for therapeutic-peptide research. Before joining Volta Peptides he held research and development roles at Amgen and Eli Lilly and Company, and served as a lecturer at the University of Michigan.
Marcus reviewed this article for scientific and analytical accuracy on September 15, 2026. He did not write it. Technical review is internal review and is not peer review, independent third-party review or medical review.
Disclosure. Marcus Hopkin is an employee of Volta Peptides and serves as its Director of Research and Development. Volta Peptides sells research compounds related to subjects discussed in the content he writes and reviews. His reviews are internal scientific and technical review and must not be described as independent third-party review, peer review or medical review.